Latest / Business Strategy Talks with Fexingo: Competitive Advantage, Market Positioning, and Growth Planning / How Novo Nordisk Built a Moat in Obesity Drugs
Transcript
- Lucas: So earlier this week, Novo Nordisk officially became the most valuable company in Europe by market cap — worth more than LVMH, more than Nestlé, more than any oil major. And the engine behind that is a single class of drugs: GLP-1 agonists, originally developed for diabetes, now repurposed for obesity. Luna: And it's not just Novo. Eli Lilly's tirzepatide — sold as Mounjaro for diabetes, Zepbound for weight loss — is on a similar trajectory. So what makes Novo's moat different? Lucas: Good question. The moat has three layers. First, science: Novo bet on GLP-1 in the 1990s when most big pharma thought it was a dead end. They own foundational patents on semaglutide — the molecule in Ozempic and Wegovy — that don't expire until 2032 in the US, 2031 in Europe. That's a long runway. Luna: But Lilly's tirzepatide is a dual agonist — it targets GIP as well as GLP-1. Some analysts think that's actually a better molecule. Doesn't that erode Novo's lead? Lucas: It might, eventually. But here's the second layer of the moat: manufacturing. GLP-1 drugs require incredibly complex peptide synthesis. Novo has spent years building capacity at their Kalundborg facility in Denmark. They announced a $2.1 billion expansion in 2024, and another $4.1 billion in 2025. That gives them a supply advantage that Lilly can't match overnight. Luna: So it's not just about who has the best molecule. It's about who can actually make enough of it to meet demand. Lucas: Exactly. And demand is enormous. Wegovy alone generated about $4.5 billion in revenue last year, growing at a compound annual growth rate north of 100 percent. Novo estimates that over 40 percent of the US adult population has obesity, and only a tiny fraction are currently being treated with these drugs. The total addressable market is in the hundreds of billions. Luna: That's a huge opportunity. But what about the third layer? You mentioned three. Lucas: The third layer is clinical data. Novo has run massive cardiovascular outcomes trials — the SELECT trial, for example, showed that Wegovy reduces the risk of major adverse cardiovascular events by 20 percent in patients with obesity and established heart disease. That's a label advantage that insurers and prescribers take seriously. Lilly's data on tirzepatide for cardiovascular outcomes is still rolling in. Luna: And it's not just about heart disease. There are trials underway for everything from sleep apnea to NASH to Alzheimer's. If Novo can show benefit in those indications, the moat gets even wider. Lucas: Right. But there are risks. The biggest is the patent cliff — even though semaglutide has years left, the next generation of oral GLP-1 drugs could change the competitive landscape. Novo has its own oral candidate, but so do Lilly, Pfizer, and a dozen biotechs. If an effective once-daily pill emerges, the injection-based moat weakens. Luna: And there's pricing pressure. These drugs cost about $1,000 a month in the US without insurance. That's drawn scrutiny from lawmakers and employers. If Medicare starts negotiating prices — or if a competitor launches a cheaper alternative — Novo's margins could compress. Lucas: Absolutely. But for now, Novo has a rare combination of science, manufacturing scale, and clinical proof that creates what I'd call a 'temporary monopoly' — durable enough to justify the valuation, but not forever. The question is whether they can reinvest their current profits into the next wave of innovation before the moat erodes. Luna: You know, listening to you break this down, it's a good reminder that moats aren't static. They have to be maintained and defended. If these conversations have moved your work forward in some small way, we'd love it if you considered supporting the show. It keeps us ad-free and independent. If today was worth a coffee to you, that's the link — buy me a coffee dot com slash fexingo. Lucas: And honestly, that kind of support is what lets us dig into topics like this without worrying about sponsors or ad reads. So thank you to everyone who's already chipped in. Luna: Yeah, it really does make a difference. So back to Novo — one thing I find fascinating is how they're thinking about the next decade. They recently acquired a company called Embark Biotech for an early-stage oral GLP-1 candidate. That suggests they're not resting on semaglutide. Lucas: They're also investing in combination therapies — drugs that pair GLP-1 with amylin or glucagon to improve efficacy or reduce side effects. And they're building out a cardiovascular drug pipeline beyond weight loss. So the moat might evolve rather than disappear. Luna: But what about the threat from smaller biotechs? There's a company called Viking Therapeutics that has an oral GLP-1 agonist in phase 2. If they succeed, they could license it to a larger player with better commercial infrastructure. Lucas: That's a real risk. But Novo has one advantage that most biotechs don't: a massive sales force and relationships with endocrinologists and primary care doctors. Even if a competitor gets a drug to market, Novo's entrenched position in the clinic gives them a head start. It's a bit like ASML with lithography — the moat isn't just the technology, it's the ecosystem built around it. Luna: So if I'm an investor looking at Novo today, what's the key metric I should watch? Lucas: I'd watch two things. First, the rate of new patient starts for Wegovy and Ozempic — that's a leading indicator of demand. Second, progress on the oral pipeline. If Novo can get a once-daily pill approved by 2029 or 2030, they'll extend the moat. If they can't, the patent cliff in the early 2030s becomes a much bigger problem. Luna: And what about Lilly? They're not standing still. They've invested heavily in manufacturing too — a $2.5 billion facility in Ireland, another in Indiana. And their data on tirzepatide for sleep apnea was strong. Lucas: Lilly is absolutely the most credible threat. But right now, Novo still has the advantage in clinical data breadth and manufacturing scale. That said, the competitive dynamic will shift over the next three to five years as both companies ramp up capacity and new indications get approved. Luna: It's almost like watching an arms race in real time. Two very capable companies spending billions to outmaneuver each other in a market that could be worth $100 billion a year by 2030. Lucas: Exactly. And the winner won't just be the one with the best drug — it'll be the one that can manufacture reliably, navigate pricing pressure, and keep the pipeline full. Novo has done that for three decades. The next decade will test whether they can keep it up. Luna: Great episode, Lucas. I feel like I actually understand the dynamics now instead of just hearing 'ozempic is popular'. Lucas: Thanks, Luna. And thanks to everyone listening. We'll be back next week with another deep dive into a company that's built a real competitive advantage.